PT  - JOURNAL ARTICLE
AU  - Haoyi Wang
AU  - Hanne M. L. Zimmermann
AU  - David van de Vijver
AU  - Kai J. Jonas
TI  - Intention and preference for long-acting injectable PrEP among MSM in the Netherlands: a diffusion of innovation approach
AID  - 10.1101/2022.11.11.22282218
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.11.11.22282218
4099  - http://medrxiv.org/content/early/2022/11/11/2022.11.11.22282218.short
4100  - http://medrxiv.org/content/early/2022/11/11/2022.11.11.22282218.full
AB  - Long-acting injectable PrEP (LAI-PrEP) is efficacious in preventing HIV among MSM and will be soon available in Europe. This study investigates the intention to use LAI-PrEP among MSM in the Netherlands by employing a diffusion of innovation approach, comparing PrEP naïve, discontinued MSM, oral PrEP early adopters and majority users. 309 MSM were surveyed on their intention and preference of LAI-PrEP. 83% showed high/very-high interest of, and 63% showed high/very-high intention to use LAI-PrEP. Early-adopters of oral PrEP use did not show increased intention to use LAI-PrEP and neither did PrEP naïve nor PrEP discontinued MSM, indicating a missing innovator effect for LAI-PrEP. Among the 218 current oral PrEP users, suboptimal oral PrEP adherence determined LAI-PrEP preference but did not determine LAI-PrEP intention. To reach the full potential of LAI-PrEP, a targeted strategy towards current oral PrEP users with suboptimal adherence seems indicated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding source for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was assessed and approved by the Ethics Review Committee Psychology and Neuroscience of Maastricht University (ERCPN-174_10_12_2016).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request.